The Use of a Quality of Life Questionnaire in Patients With Lung Cancer
Conditions
Lung Cancer
Conditions: official terms
Lung Neoplasms
Conditions: Keywords
lung, cancer, quality of life
Study Type
Interventional
Study Phase
N/A
Study Design
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care
Intervention
Name: Intervention Type: Other
Name: Attention Type: Other
Name: Control Type: Other
Overall Status
Recruiting
Summary
This study will investigate the effectiveness of using the European Organisation for Research and Treatment of cancer Core Quality of Life Questionnaire (EORTC QLQ-C30 + LC 13) to identify and target therapies in patients with lung cancer. The study will assess whether using the questionnaire will result in an improvement in QoL.
Detailed Description
Patients with lung cancer who have completed a course of treatment (or who are in-between treatment) at the Royal Marsden Hospital would be eligible for inclusion in the study. Participants will be randomised into 3 groups. Group 1 - this group will complete the QoL questionnaire and will receive targeted therapies by a doctor (and other members of the oncology team) during a clinic consultation. Group 2 - will complete the QoL questionnaire however the questionnaire will not be seen by the doctor during a clinic consultation. Group 3 - the control group will not complete the QoL questionnaire before a clinic consultation. All patients will complete a diary of all contact they have with health care professionals during the study. The study will last for 6 weeks and at the end of the study all patients will complete the QoL questionnaire.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- male or female age > 18 years

- patients who are able to adequately understand written and spoken english

- diagnosis of lung cancer (non small cell, small cell, mesothelioma)

- no plan to commence treatment (chemotheraphy, targeted therapies, radioterhapy, surgery) with 6 weeks

- both radically or palliatively treated patients remain eligible

- patients whose toxicities from their primary treatment has resolved or have stabilised for a period of 7 days

Exclusion Criteria:

- patients are taking part on any other QoL studies

- taking part in any other studies that requires QoL questionnaires, extra visits or investigations

- currently on treatment (chemotherapy, radiotherapy, surgery or targeted therapies)

- they have on going toxicities from their treatment which have not been stablised (required intervention within last 7 days)
Location
Royal Marsden NHS Foundation Trust
Sutton, United Kingdom
Status: Recruiting
Contact: Dr M O'Brien - 02086613278 - mary.o'brien@rmh.nhs.uk
Start Date
September 2010
Completion Date
July 2012
Sponsors
Royal Marsden NHS Foundation Trust
Source
Royal Marsden NHS Foundation Trust
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page